Disclaimer: You are now leaving www.HIVReagentProgram.org and are going to a website that is not operated by NIH HIV Reagent Program. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE:
NIH HIV Reagent Program offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the NIH HIV Reagent Program website and will be redirected to another site. These sites are not under the control of NIH HIV Reagent Program.
NIH HIV Reagent Program is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Please read third party privacy and security policies closely as these may be different than NIH HIV Reagent Program policies.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.
colder, preferably in the vapor phase of a liquid nitrogen freezer
Quantity limit per order for this item is 1. This item can be
ordered twice a year. Orders over this limit will be sent to NIAID for approval
ARP-2187 expresses high levels of CD4 and are permissive to infection by human immunodeficiency virus 2 (HIV-2) and Simian immunodeficiency virus (SIV), but not HIV-1. ARP-2187 is derived from the parental U87MG cells, a human astroglioma cell line, transformed with a retroviral vector containing human CD4 and neomycin resistance genes.
Growth Characteristics: ARP-2187 has an epithelial-like morphology.
Growth Media: DMEM supplemented with 10% fetal bovine serum or 10% fetal calf serum
ARP-2187 is negative for Mycoplasma, bacteria and fungi.
Each vial of ARP-2187 contains
approximately 1.2 × 107 cells per mL in DMEM supplemented with 50% fetal bovine serum and 10% dimethyl sulfoxide (DMSO).
Please refer to the
attached file(s) for more information.
T. and M. Alizon. “Different Requirements for Membrane Fusion Mediated by the Envelopes
of Human Immunodeficiency Virus Types 1 and 2.” J. Virol. 67
(1993): 2355-2359.PubMed: 8095307.
Chesebro, B., et al. “Failure of Human Immunodeficiency Virus
Entry and Infection in CD4-Positive Human Brain and Skin Cells.” J. Virol.
64 (1990):215-221. PubMed: 2293663.
J. and E. H. MacIntyre. “Long-Rerm Culture of Normal and Neoplastic Human Glia.”
Acta Pathol. Microbiol. Scand. 74 (1968): 465-486. PubMed: 4313504.
When applying for permits and forms please:
Do NOT reference NIH HIV Reagent Program or ATCC Catalog Numbers in the Material Description
fields found on the permits and/or forms.
Make sure your name and address on the permit applications and/or forms are exactly
as they appear on your NIH HIV Reagent Program registration.
Information about permits is provided as a courtesy to NIH HIV Reagent Program customers.
While we use reasonable efforts to include accurate and up-to-date information on
this page, we make no warranties or representation as to its accuracy.
For more information on the necessary compliance requirements associated with the
biological materials provided by NIH HIV Reagent Program, please select this link: Compliance Requirements.
Knowledge Base (FAQs)
Microsoft PowerPoint Viewer
Microsoft Word Viewer
Microsoft Excel Viewer
Call Us Toll-Free:+1 (888) 487-0727
TTY:(703) 365 - 2727 (for deaf, hard of hearing, or speech impaired)